Compare HTBK & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | CMPS |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 662.5M |
| IPO Year | 1998 | 2020 |
| Metric | HTBK | CMPS |
|---|---|---|
| Price | $13.44 | $7.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $12.88 | ★ $16.86 |
| AVG Volume (30 Days) | 666.0K | ★ 1.3M |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ 18.01 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,648,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | ★ 14.91 | N/A |
| 52 Week Low | $8.09 | $2.25 |
| 52 Week High | $13.83 | $8.20 |
| Indicator | HTBK | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 60.83 |
| Support Level | $13.07 | $5.77 |
| Resistance Level | $13.83 | $6.38 |
| Average True Range (ATR) | 0.35 | 0.49 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 68.91 | 59.26 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.